Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 314

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg250 · Cited by 277

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

Jones, H., Stafford, L. E., Swaisland, H., & Payne, R. K. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00014-6 · Cited by 63

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future

Proto, C., Imbimbo, M., Gallucci, R., Brissa, A., Signorelli, D., Vitali, M., Macerelli, M., Corrao, G., Ganzinelli, M., Greco, F. G., et al. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.16 · Cited by 37

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Ricciuti, B., Baglivo, S., Giglio, A. D., & Chiari, R. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618808659 · Cited by 39

Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy

Economopoulou, P., & Mountzios, G. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.12.06 · Cited by 40

Successful Treatment of Carcinomatous Meningitis with Gefitinib in a Patient with Lung Adenocarcinoma Harboring a Mutated EGF Receptor Gene

Fukuhara, T., Saijo, Y., Sakakibara, T., Inoue, A., Morikawa, N., Kanamori, M., Nakashima, I., & Nukiwa, T. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.214.359 · Cited by 37

EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer

Bartolotti, M., Franceschi, E., & Brandes, A. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.121 · Cited by 36

EGFR-Mutated Lung Cancer WithT790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

Scher, K. S., Saldivar, J., Fishbein, M. C., Marchevsky, A. M., & Reckamp, K. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0126 · Cited by 36

Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)

Andratschke, N. H., Kraft, J., Nieder, C., Tay, R. Y., Califano, R., Soffietti, R., & Gückenberger, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.009 · Cited by 35

The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma

Zhuang, H., Wang, J., Zhao, L., Yuan, Z., & Wang, P. (2013) · International Journal of Cancer · doi:10.1002/ijc.28290 · Cited by 34

Histopathologic diagnosis of brain metastases: current trends in management and future considerations

Bekaert, L., Emery, É., Levallet, G., & Lechapt, E. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0275-3 · Cited by 32

Systemic therapy for brain metastases

Venur, V. A., Karivedu, V., & Ahluwalia, M. S. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00011-6 · Cited by 32

Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer

Kinoshita, Y., Koga, Y., Sakamoto, A., & Hidaka, K. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-200867 · Cited by 31

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis

Rau, K., Chen, H.-K., Shiu, L., Chao, T.-L., Lo, Y.-P., Wang, C., Lin, M., & Huang, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040524 · Cited by 31

Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study

Fan, W.-C., Yu, C., Tsai, C., Huang, M.-S., Lai, C.-L., Hsia, T., Tien, Y.-J., Huang, S., Wu, C.-H., Chou, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f77b27 · Cited by 28

Molecular Pathology of Lung Cancer

Solis, L. M., & Wistuba, I. I. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0787-5_14 · Cited by 27

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

Zhai, X., Li, W., Li, J., Jia, W., Wang, J., Tian, Y., Xu, S., Li, Y., Zhu, H., & Yu, J. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01955-7 · Cited by 27

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases

Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 25

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Peled, N., Kian, W., Inbar, E., Goldstein, I. M., Zemel, M., Rotem, O., Rozenblum, A. B., Nechushtan, H., Dudnik, E., Levin, D., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab188 · Cited by 27

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer

Metro, G., Chiari, R., Ricciuti, B., Rebonato, A., Lupattelli, M., Gori, S., Bennati, C., Castrioto, C., Floridi, P., Minotti, V., et al. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1094056 · Cited by 26

Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.

Inomata, M., Shukuya, T., Takahashi, T., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Murakami, H., Harada, H., et al. (2011) · PubMed · Cited by 26

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

Chien, A. J., & Rugo, H. S. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2328-6 · Cited by 25

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)

Ferguson, S. D., Fomchenko, E. I., Guerrieri, R. A., & Oliva, I. C. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800053 · Cited by 24

Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?

Song, T., Yu, W., & Wu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.205 · Cited by 25

DHPLC/SURVEYOR Nuclease: A Sensitive, Rapid and Affordable Method to Analyze BRCA1 and BRCA2 Mutations in Breast Cancer Families

Pilato, B., Summa, S. D., Danza, K., Papadimitriou, S., Zaccagna, P., Paradiso, A., & Tommasi, S. (2011) · Molecular Biotechnology · doi:10.1007/s12033-011-9468-5 · Cited by 24

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Lee, J. C., Jang, S. H., Lee, K. Y., & Kim, Y. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.2.79 · Cited by 24

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101)

Nosaki, K., Yamanaka, T., Hamada, A., Shiraishi, Y., Harada, T., Himeji, D., Kitazaki, T., Ebi, N., Shimose, T., Seto, T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0640 · Cited by 23

Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug

Lee, Y., Kim, H. Y., Lee, S.-H., Lim, K. Y., Lee, G. K., Yun, T., Han, J., Kim, H. T., & Lee, J. S. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.008 · Cited by 23

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation

Koba, T., Kijima, T., Takimoto, T., Hirata, H., Naito, Y., Hamaguchi, M., Otsuka, T., Kuroyama, M., Nagatomo, I., Takeda, Y., et al. (2017) · Medicine · doi:10.1097/md.0000000000006087 · Cited by 22

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Choi, M., Keam, B., Ock, C.-Y., Kim, M., Kim, T. M., Kim, D., & Heo, D. S. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.03.005 · Cited by 22

Leptomeningeal Metastases

Bruna, J., Simó, M., & Velasco, R. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0182-9 · Cited by 22

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors

Bohn, J., Pall, G., Stockhammer, G., & Steurer, M. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0414-5 · Cited by 21

Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer

Bui, N. Q., Woodward, B. D., Johnson, A., & Husain, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0400-x · Cited by 21

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation

Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Lu, Y., & Fan, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95871 · Cited by 20

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations

Rossi, A., & Galetta, D. (2022) · Cancers · doi:10.3390/cancers14030832 · Cited by 20

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

Kim, H.-R., Lee, J. C., Kim, Y., Kim, K. S., Oh, I., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.008 · Cited by 21

Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib

Tetsumoto, S., Osa, A., Kijima, T., Minami, T., Hirata, H., Takahashi, R., Kuhara, H., Nagatomo, I., Takeda, Y., Kida, H., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0256-9 · Cited by 19

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Xu, Y., Binbin, S., Wenyu, C., Liu, J., & Xinmei, Y. (2016) · SpringerPlus · doi:10.1186/s40064-016-2873-2 · Cited by 19

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review

Pareek, V., Welch, M. R., Ravera, E., Zampolin, R. L., Sequist, L. V. D., & Halmos, B. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.010 · Cited by 18

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

Pan, M., Santamaria, M., & Wollman, D. B. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0931 · Cited by 18

Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

Tang, Z., Jiang, S., Du, R., Petri, E. T., El-Telbany, A., Chan, P. S. O., Kijima, T., Dietrich, S., Matsui, K., Kobayashi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.411 · Cited by 18

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis

Jia, C., Xu, Q., Zhao, L., Kong, F., & Jia, Y. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101832 · Cited by 17

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Yuan, Y., Tan, C., Li, M., Shen, H., Fang, X., Hu, Y., & Ma, S. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-235 · Cited by 17

Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non–Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?

Hata, A., & Katakami, N. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000479 · Cited by 16

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

Hyun, D., Choi, C., Lee, K. H., Kim, S., Yoon, S., Kim, W. S., Ji, W., & Lee, J. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231546 · Cited by 15

Targeted Therapy for Brain Metastases

Davies, M. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00005-1 · Cited by 16

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Schoenmaekers, J. J. A. O., Paats, M. S., Dingemans, A. C., & Hendriks, L. E. L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-459 · Cited by 13

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Lee, C., Sharma, S., Miao, E., Mensah, C., Sullivan, K. M., & Seetharamu, N. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s258444 · Cited by 15

Brain Metastases from Non-Small Cell Lung Cancer

Fekrazad, M. H., Sanaei, O., Bauman, J. E., & Jones, D. V. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800896-6.00014-0 · Cited by 14

Targeted therapy for neuro-oncology: reviewing the menu

Lampson, L. A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.003 · Cited by 14

Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.

Nakamura, Y., Takahashi, T., Tsuya, A., Naito, T., Kenmotsu, H., Ono, A., Shukuya, T., Murakami, H., Harada, H., Watanabe, R., et al. (2012) · PubMed · Cited by 13

CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer

Suryavanshi, M., Jaipuria, J., Panigrahi, M. K., Goyal, N., Singal, R., Mehta, A., Batra, U., Doval, D. C., & Talwar, V. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.034 · Cited by 13

Exosomal Long Noncoding RNAs in NSCLC: Dysfunctions and Clinical Potential

Lin, H., Li, J., Wang, M., Zhang, X., & Zhu, T. (2023) · Journal of Cancer · doi:10.7150/jca.84506 · Cited by 15

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Bian, D. J. H., Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Zeng, Z., Zhu, Z., Sener, U. T., Malani, R., Kim, Y. J., Ichihara, E., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29668 · Cited by 12

Experimental Treatments for Leptomeningeal Metastases from Solid Malignancies

Sahebjam, S., Forsyth, P. A., Smalley, K. S. M., & Tran, N. (2017) · Cancer Control · doi:10.1177/107327481702400106 · Cited by 12

Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors

O'Kane, G. M., & Leighl, N. B. (2018) · CNS Drugs · doi:10.1007/s40263-018-0526-4 · Cited by 12

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR ‐mutant lung cancer

Kim, D. H., Choi, Y. J., Sung, K. J., Yoo, S., Sung, Y. H., Kim, J. K., Choi, C., Yun, M., Lee, E. Y., Jin, Y. S., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12394 · Cited by 12

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer

Tozuka, T., Noro, R., Miyanaga, A., Nakamichi, S., Takeuchi, S., Matsumoto, M., Kubota, K., Kasahara, K., & Seike, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6393 · Cited by 11

Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study

van der Wel, T. J. W. T., Boelens, M. C., Jebbink, M., Smulders, S. A., Maas, K. W., Luitse, M. J. A., Compter, A., Boltjes, R. P. B., Sol, N., Monkhorst, K., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae138 · Cited by 11

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

Kogure, Y., Saka, H., Oki, M., Saito, T. I., Ahmed, S. N. M., Kitagawa, C., & Imaizumi, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135393 · Cited by 11

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report

Ohara, S., Ushijima, T., Gunji, M., Tanai, C., Tanaka, Y., Noda, H., Horiuchi, H., & Usui, K. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-64 · Cited by 11

Long-term Outcome after Multidisciplinary Approach for Leptomeningeal Carcinomatosis in a Non-small Cell Lung Cancer Patient with Poor Performance Status

Nagano, T., Kotani, Y., Kobayashi, K., Hatakeyama, Y., Hori, S., Kasai, D., Funada, Y., Nishimura, H., Kondoh, T., & Nishimura, Y. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5903 · Cited by 11

Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Lewitzki, V., Andratschke, N. H., Kuhnt, T., & Hildebrandt, G. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0334-7 · Cited by 11

Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non–Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm

Bover, M., Yarza, R., & Docampo, L. I. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.012 · Cited by 11

Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report

de Jong, L. A. W., Sparidans, R. W., & van den Heuvel, M. M. (2023) · Case Reports in Oncology · doi:10.1159/000535172 · Cited by 10

Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience

Kato, Y., Hotta, K., Takigawa, N., Nogami, N., Kozuki, T., Satô, A., Ichihara, E., Kudo, K., Oze, I., Tabata, M., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2425-9 · Cited by 10

Role of Chemotherapy on Brain Metastasis

Lee, S. (2012) · Progress in neurological surgery · doi:10.1159/000331183 · Cited by 10

Traitement systémique des métastases cérébrales de cancer bronchique

Barlési, F., Spano, J., Cortot, A. B., Carpentier, A. F., Robinet, G., & Besse, B. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2014.12.001 · Cited by 9

First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review

Chen, Y.-M., Whang‐Peng, J., & Chen, C. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.04.008 · Cited by 9

PP03. HUMAN ENDOGENOUS RETROVIRUS TYPE K (HERVK) PROTEINS ARE OVEREXPRESSED AND RELEASED FROM HUMAN PRIMARY SCHWANNOMA CELLS CONTRIBUTING TO TUMOUR DEVELOPMENT VIA ERK, AKT, FAK PATHWAYS ACTIVATION AND P53 DOWNREGULATION

Ammoun, S., Maze, M. E., Reeves, S., Hilton, D. A., Ercolano, E., Hamemann, P. O., & Belshaw, R. D. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now293.002 · Cited by 9

Inhibitory effects of Olea ferruginea crude leaves extract against some bacterial and fungal pathogen.

Amin, A., Khan, M. A., Shah, S., Ahmad, M., Zafar, M. N., & Hameed, A. (2013) · PubMed · Cited by 9

Molecular Diagnostics of Lung Cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: Technology in Rapid Evolution

Lindeman, N. I. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0277-ra · Cited by 8

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation

Kubo, T., Morichika, D., Gotoda, H., Tamura, T., Ohashi, K., Hotta, K., Tabata, M., Kurozumi, K., Tanimoto, M., & Kiura, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95721 · Cited by 8

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases

Xu, J., Zhou, L., Lü, Y., Su, X., Cheng, P., Li, D., Gao, H., Li, H., Yuan, W., Zhang, L., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s230399 · Cited by 8

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases

Shriyan, B., Patil, D., Gurjar, M., Nookala, M., Patil, A., Kannan, S., Patil, V., Joshi, A., Noronha, V., Prabhash, K., et al. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02926-9 · Cited by 8

Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor

Zheng, H., Wang, Q., Shi, H., Zhang, H., Hu, F., & Li, B. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12096 · Cited by 7

Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer HarboringEGFRMutation

Jang, S. H. (2014) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2014.76.1.8 · Cited by 7

The Diagnosis and Treatment of Brain Metastases in EGFR Mutant Lung Cancer

Minchom, A. R., Yu, K. C., Bhosle, J., & O’Brien, M. (2014) · CNS Oncology · doi:10.2217/cns.14.19 · Cited by 7

Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports

Xing, P., Li, J., Shi, Y., & Zhang, X. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12049 · Cited by 7

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

Kuiper, J. L., Heideman, D. A. M., Thunnissen, E., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.005 · Cited by 7

Dose Reduction or Intermittent Administration of Erlotinib: Which Is Better for Patients Suffering from Intolerable Toxicities?

Hata, A., Fujita, S., Kaji, R., Nanjo, S., & Katakami, N. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8543 · Cited by 8

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro

Li, Y., Liu, Y., Ying, X., Zhou, H., Wang, Z., Wu, S., Yan, J., Jing, Y., & Yang, Y. (2017) · Biotechnology Progress · doi:10.1002/btpr.2564 · Cited by 7

Current progress and outcomes of clinical trials on using epidermal growth factor receptor‐tyrosine kinase inhibitor therapy in non‐small cell lung cancer patients with brain metastases

Kong, L., Wang, L., Xing, L., & Yu, J. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.11.001 · Cited by 7

Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Yu, M., Zhao, Q., Li, Y., Zhang, S., Xu, Y., Gong, Y., Zhu, J., Ding, Z., Wang, J., Peng, F., et al. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2493 · Cited by 7

Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer

Lin, G., Wang, Y., Xin, T., Zhang, D., Zhang, Q., Li, Y.-S., Chi, Y., Fan, Y., Liu, A., Xu, H., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70088 · Cited by 6

The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases

Zhou, J., Zhou, Y., Sun, Y., Li, X., Lu, H., Yin, X., & Fan, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1259880 · Cited by 6

The effect of radiotherapy on patients with EGFR-driven lung cancer brain metastasis: a systematic review and meta-analysis

Habibi, M. A., Rashidi, F., Delbari, P., Hajikarimloo, B., Hojjat, S. H., Kazemivand, S., Tavani, S. F., Bahri, A., Eftekhar, M. S., Gandomkar, H., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02780-0 · Cited by 6

Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis

Okuda, T., Hayashi, H., Fujita, M., YOSHIOKA, H., Tasaki, T., Nakagawa, K., & Kato, A. (2013) · International Cancer Conference Journal · doi:10.1007/s13691-013-0148-0 · Cited by 6

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment

Xu, H., Ma, D., Yang, G., Li, J., Hao, X., Xing, P., Yang, L., Xu, F., & Wang, Y. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.02.09 · Cited by 6

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment

Hwang, J. A., Lee, J. Y., Kim, W. S., Song, J. S., Rho, J. K., Choi, C., & Lee, J. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.018 · Cited by 5

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis

Dong, Y. Q., Li, Q., Miao, Q., & Li, D. (2021) · Medicine · doi:10.1097/md.0000000000026450 · Cited by 5

Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib

Takenaka, T., Yamagata, M., Fukuda, A., & Sonoda, T. (2011) · BMJ Case Reports · doi:10.1136/bcr.08.2011.4586 · Cited by 5

Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: A case report and review of the literature

Bai, C., Shi, H. R., Liu, D., ZHU, T., Hu, Z., & Li, Q. (2013) · Oncology Letters · doi:10.3892/ol.2013.1263 · Cited by 5

Inhibiting Kinases in the CNS

Tsui, H., Zeng, Q., Chen, K., & Zhang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13815-6 · Cited by 5

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy

Wu, S., Qiu, Z., Shi, H., Yu, W., Liu, L., Wu, L., & Zhong, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-14337-z · Cited by 4

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib

Leitner, C., von Moos, R., Mark, M. T., Früh, M., & Cathomas, R. L. (2014) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2014.03.001 · Cited by 4

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report

Fan, F. S. (2016) · Case Reports in Oncology · doi:10.1159/000449405 · Cited by 4

Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma

Sano, S., Asahi, Y., Kamiyama, T., Kakisaka, T., Orimo, T., Nagatsu, A., Aiyama, T., Kazui, K., Shomura, H., Ueki, S., et al. (2022) · International Cancer Conference Journal · doi:10.1007/s13691-022-00567-6 · Cited by 4

Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma.

Wong, E. T., Wu, J. K., & Mahadevan, A. (2007) · Europe PMC (PubMed Central) · Cited by 4

The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients

Zhao, Y., Gao, X., & Han, Y. C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1543416 · Cited by 3

Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib

Kiura, K., Takigawa, N., & Segawa, Y. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_21 · Cited by 3

Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.

Panther, L., Schlecht, H. P., & Dezube, B. J. (2005) · PubMed · Cited by 24

Anale intraepitheliale Neoplasie und Analkarzinom

Kreuter, A., Brockmeyer, N. H., & Wieland, U. (2009) · Der Hautarzt · doi:10.1007/s00105-009-1810-5 · Cited by 14

Anal cancer and its precursors in HIV-positive patients: perspectives and management

Berry, J. M., Palefsky, J. M., & Welton, M. L. (2004) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2003.12.003 · Cited by 93

HPV-Associated Anal Cancer in the HIV/AIDS Patient

Wang, C.-C. J., & Palefsky, J. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-030-03502-0_7 · Cited by 63

Anal intraepithelial neoplasia and squamous cell carcinoma in HIV ‐infected adults

Tong, W., Hillman, R. J., Kelleher, A. D., Grulich, A., & Carr, A. D. (2013) · HIV Medicine · doi:10.1111/hiv.12080 · Cited by 42